Meeting
2019 Gastrointestinal Cancers Symposium
Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).
Authors
Andrea S. Fung
Tom Baker Cancer Centre, Calgary, AB, Canada
Andrea S. Fung , Vincent C. Tam , Daniel E. Meyers , Hao-Wen Sim , Jennifer J. Knox , Valeriya O. Zaborska , Janine Marie Davies , Yoo-Joung Ko , Eugene Batuyong , Winson Y. Cheung , Haider Samawi , Richard M. Lee-Ying
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 422)
DOI
10.1200/JCO.2019.37.4_suppl.422
Abstract #
422
Poster Bd #
N2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.
First Author: M. Naomi Horiba
Poster
2020 Gastrointestinal Cancers Symposium
Eligibility for second-line therapy in patients with advanced hepatocellular carcinoma (aHCC): A BC Cancer population-based study.
First Author: Erica S. Tsang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real world data of systemic therapy for hepatocellular carcinoma in Japan: HERITAGE study.
First Author: Yoshinari Asaoka
Poster
2019 Gastrointestinal Cancers Symposium
Hepatic arterial infusion chemotherapy after sorafenib treatment in patients with advanced hepatocellular carcinoma who are unfit for regorafenib.
First Author: Takeshi Terashima